Mfg News: Pfizer, CSL’s Seqirus & Regenxbio
A roundup of manufacturing news from Pfizer, CSL’s Seqirus, and Regenxbio. Highlights below.
Pfizer Opens $313-M Drug-Product Mfg Facility in Germany
Pfizer has opened a new EUR 300-million ($313-million) high-containment drug-product manufacturing facility in Freiburg, Germany. The facility, which was built with Bristol-Myers Squibb, will support Pfizer CentreOne, Pfizer’s CDMO business embedded within Pfizer.
At 13,500 m2, the new Freiburg facility is capable of producing up to 7 billion additional solid dosage forms. Overall, the site has now increased its total capacity to produce up to 12 billion tablets and capsules per year.
Source: Pfizer CentreOne
CSL’s Seqirus Completes $156-M Vaccines Mfg Expansion
Seqirus, a subsidiary of CSL Limited, a Melbourne, Australia-based bio/pharmaceutical company, has completed a $156-million expansion of its manufacturing facility in Holly Springs, North Carolina, to support the formulation and fill–finish of cell-based influenza vaccines in pre-filled syringes.
The new pre-filled syringe line will support influenza vaccine production for the 2022/2023 Northern Hemisphere season and beyond and also enhance the site’s ability to respond to an influenza pandemic.
With the expansion, the Holly Springs facility now has two fill–finish lines. The new fill–finish line will support production of Flucelvax Quadrivalent (influenza vaccine), a cell-based quadrivalent influenza vaccine
In addition to Holly Springs, Seqirus has sites in Liverpool, UK, and Parkville, Australia, to support seasonal and pandemic influenza vaccine production. A new facility is currently under construction in Tullamarine, Australia.
Regenxbio Opens Gene-Therapy Mfg Facility
Regenxbio, a Rockville, Maryland-based bio/pharmaceutical company, has opened a new gene-therapy manufacturing facility in Rockville, Maryland.
Located in Regenxbio’s 132,000-square-foot headquarters, the facility, the Manufacturing Innovation Center, will enable the company to boost manufacturing of its NAV Technology-based adeno-associated virus (AAV) vectors at scales up to 2,000 liters. The company’s NAV Technology Platform is proprietary AAV gene-delivery platform.
Regenxbio invested more than $100 million into the build-out of its Rockville headquarters, including more than $65 million dedicated to the Manufacturing Innovation Center. The company has also has hired 200 people over the past two years (as reported on June 9, 2022).